#ESMO23 Dr. @DoctorJSpicer presents OS data from KEYNOTE 671: neoadjuvant pembrolizumab + chemotherapy followed by surgery and adjuvant pembro x 1 year. Perioperative IO improves survival. OS HR 0.72, 3y OS rate 71% vs 64%, impressive tails. Now an FDA approved standard.
This is a great speech from @Rove but the reason it’s getting so much praise & reach today is that this kind of reporting has been so shamefully absent from the lying media coverage of the referendum to date & their collective “about face” now seems designed only to limit their own culpability in the coming probable failure.
Where were these speeches a month ago when they might have made a damn difference?
Stereotactic radiation + anti-angiogenesis = pulmonary hemorrhage? Prospective cohort of 690 pts treated with SABR +/- VEGF therapy across tumors. G3+ pulmonary hemorrhage at 3y was 7.9% vs 0.6% with SABR alone (higher in central tumors, 19.1% vs 3.3%).
https://t.co/ZedYxCWjRk
Every ED shift reminds me how much we need to rebuild, reimagine and reinvest in our health systems….it’s a huge task. We have a common goal. Let’s NOT accept this current state as the “new normal”..it’s very abnormal #BuildBackBetter